Real-World Clinical and Economic Outcomes and the Role of Bevacizumab in Patients With Non–Small-Cell Lung Cancer With Liver Metastases release_a6rxn5lzfjce3punosky4m5ppy

by William B. Wong, Ning Wu, Erru Yang, Jessica Davies, Young Kwang Chae

Published in Journal of Oncology Practice by American Society of Clinical Oncology (ASCO).

2019   Volume 15, Issue 10, JOP.19.00166

Abstract

Liver metastases are associated with poor outcomes in patients with advanced non-small-cell lung cancer (aNSCLC). Nevertheless, the vasculature in the liver microenvironment may be conducive to the use of antiangiogenesis inhibitors to potentially improve outcomes. Limited real-world clinical and economic data are currently available for this patient subpopulation.
In text/plain format

Archived Content

There are no accessible files associated with this release. You could check other releases for this work for an accessible version.

"Dark" Preservation Only
Save Paper Now!

Know of a fulltext copy of on the public web? Submit a URL and we will archive it

Type  article-journal
Stage   published
Date   2019-09-11
Language   en ?
Journal Metadata
Not in DOAJ
In Keepers Registry
ISSN-L:  1554-7477
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 9ee3e63f-bcca-4ad2-97f5-eb1d2d377fec
API URL: JSON